The treatment of both<unk>  subtypes, when not associated with the presence of the<unk>  malignancies described above, is regular follow-ups to check for the development of these malignancies. Follow-up of 33 patients with ISFL over a period of 12 to 132 months diagnosed FL with times of progression of 15 and 29 months in two (6% of all followed) patients. Studies on the development of other types of<unk>  malignancies in ISFL are based primarily on case reports. Single studies suggest that ISFL patients who present with high levels of circulating t(13:18)(q32:q21) translocation-positive lymphocytes or Bcl2-positive lymphocytes that have mutations in the EZH2 gene are at increased risk of, and/or have a shorten time before developing, FL. Follow-up studies of patients with ISMCL are limited. ISMCL has been found to have been present 2–86 months prior to patients developing MCL but only 1 of 15 patients who were followed for >1 year developed the malignance. It has been suggested that mutations in the ATM and CHK2 genes may be associated with an increase risk of, and/or a shorten time before developing, MCL.<unk>  patients who have or develop FL, MCL, or other<unk>  malignancy are treated for their malignancies.
In situ lymphoid neoplasia
Benign lymphoepithelial lesion
Germ cell neoplasia in situ
Solitary lymphatic nodule
Intraepithelial neoplasia
Squamous intraepithelial lesion
Ductal carcinoma in situ
Epithelial dysplasia